Skip to content

Incyte INCY Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$135M-1.5%
Pfizer logo
PfizerPFE
$272M+60.0%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$8.52M-8.5%
Gilead Sciences logo
Gilead SciencesGILD
$218M+4.3%
Geron logo
GeronGERN
$4.91M-33.8%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$14.52M+5.2%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$25.96B+70.1%
Enterprise value$22.01B+64.9%
P/E16.1×-1.4×
P/S4.5×+1.1×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Incyte’s 10-Q, filed July 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's stock-based comp?
Incyte (INCY) reported stock-based comp of $67.26M in Q2 2026.
How has Incyte's stock-based comp changed year-over-year?
Incyte's stock-based comp increased by 4.1% year-over-year, from $64.61M to $67.26M.
What is the long-term trend for Incyte's stock-based comp?
Over 4 years (2021 to 2025), Incyte's stock-based comp has grown at a 8.0% compound annual growth rate (CAGR), from $183.01M to $249.35M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.